- Oops!Something went wrong.Please try again later.
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) remained unaffected after the company reported Q3 results.
Earnings per share increased 50.00% year over year to $0.15, which beat the estimate of $0.14.
Revenue of $83,431,000 up by 4.11% year over year, which missed the estimate of $91,260,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 06, 2020
Time: 12:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/4feqnxzx
Company's 52-week high was at $22.69
Company's 52-week low was at $12.32
Price action over last quarter: Up 2.43%
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.